BioPorto A/S
THOXF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.37 | 0.31 | -0.19 | 1.68 |
| FCF Yield | -2.43% | -2.09% | -2.98% | -2.17% |
| EV / EBITDA | -36.57 | -44.35 | -27.78 | -39.57 |
| Quality | ||||
| ROIC | -52.84% | -25.29% | -52.39% | -25.36% |
| Gross Margin | 74.00% | 66.67% | 64.01% | 46.79% |
| Cash Conversion Ratio | 0.88 | 0.93 | 0.78 | 0.82 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.38% | 6.40% | 4.13% | 7.75% |
| Free Cash Flow Growth | -18.60% | 33.05% | -42.56% | 31.99% |
| Safety | ||||
| Net Debt / EBITDA | 0.80 | 2.20 | 0.76 | 2.48 |
| Interest Coverage | -57.20 | -11.88 | -47.74 | 30.88 |
| Efficiency | ||||
| Inventory Turnover | 0.48 | 0.73 | 0.47 | 0.91 |
| Cash Conversion Cycle | 105.58 | 77.19 | 98.46 | 86.06 |